Advanced search
Publication Cover
Human Vaccines & Immunotherapeutics Volume 17, 2021 - Issue 8
Submit an article Journal homepage
830
Views
3
CrossRef citations to date
0
Altmetric
Case Report

Pembrolizumab for choroidal metastases from non-small cell lung cancer: a case report and literature review

Xinsheng LiDepartment of Ophthalmology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
,
Ya LiangDepartment of Ophthalmology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
,
Jingfan WangDepartment of Ophthalmology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
,
Zizhong HuDepartment of Ophthalmology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
,
Zhi-Lan YuanDepartment of Ophthalmology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, ChinaCorrespondence[email protected]
&
Ping XieDepartment of Ophthalmology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, ChinaCorrespondence[email protected]
Pages 2626-2629 | Received 03 Dec 2020, Accepted 30 Jan 2021, Published online: 26 Mar 2021

References

  • Arepalli S, Kaliki S, Shields CL. Choroidal metastases: origin, features, and therapy. Indian J Ophthalmol. 2015;63:122–27. doi:10.4103/0301-4738.154380.
  • Shields CL, Shields JA, Gross NE, Schwartz GP, Lally SE. Survey of 520 eyes with uveal metastases. Ophthalmology. 1997;104:1265–76. doi:10.1016/S0161-6420(97)30148-1.
  • Gozzi E, Angelini F, Rossi L, Leoni V, Trenta P, Cimino G, Tomao S. Alectinib in the treatment of ocular metastases of ALK rearranged non small cell lung cancer: description of 2 case reports. Medicine (Baltimore). 2020;99:e21004. doi:10.1097/MD.0000000000021004.
  • Mathis T, Jardel P, Loria O, Delaunay B, Nguyen AM, Lanza F, et al. New concepts in the diagnosis and management of choroidal metastases. Prog Retin Eye Res. 2019;68:144–76.
  • Raedler LA. Keytruda (Pembrolizumab): first PD-1 inhibitor approved for previously treated unresectable or metastatic melanoma. Am Health Drug Benefits. 2015;8:96–100.
  • Ferry AP, Font RL. Carcinoma metastatic to the eye and orbit. I. A clinicopathologic study of 227 cases. Arch Ophthalmol. 1974;92:276–86. doi:10.1001/archopht.1974.01010010286003.
  • Langley RR, Fidler IJ. The seed and soil hypothesis revisited – the role of tumor-stroma interactions in metastasis to different organs. Int J Cancer. 2011;128:2527–35. doi:10.1002/ijc.26031.
  • Diaz-Coranguez M, Ramos C, Antonetti DA. The inner blood-retinal barrier: cellular basis and development. Vision Res. 2017;139:123–37.
  • Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677–704. doi:10.1146/annurev.immunol.26.021607.090331.
  • Kwok G, Yau TC, Chiu JW, Tse E, Kwong YL. Pembrolizumab (Keytruda). Hum Vaccin Immunother. 2016;12:2777–89. doi:10.1080/21645515.2016.1199310.
  • Biton J, Mansuet-Lupo A, Pecuchet N, Alifano M, Ouakrim H, Arrondeau J, Boudou-Rouquette P, Goldwasser F, Leroy K, Goc J, et al. TP53, STK11, and EGFR mutations predict tumor immune profile and the response to anti–PD-1 in lung adenocarcinoma. Clin Cancer Res. 2018;24:5710–23. doi:10.1158/1078-0432.CCR-18-0163.
  • Wang Z, Sun K, Xiao Y, Feng B, Mikule K, Ma X, Feng N, Vellano CP, Federico L, Marszalek JR, et al. Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models. Sci Rep. 2019;9(1):1853. doi:10.1038/s41598-019-38534-6.
  • van Vugt MJH, Stone JA, De Greef R, Snyder ES, Lipka L, Turner DC, Chain A, Lala M, Li M, Robey SH, et al. Immunogenicity of pembrolizumab in patients with advanced tumors. J Immunother Cancer. 2019;7:212. doi:10.1186/s40425-019-0663-4.
  • Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A, Gottfried M, Peled N, Tafreshi A, Cuffe S, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375:1823–33. doi:10.1056/NEJMoa1606774.
  • Gandhi L, Rodriguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ, Powell SF, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378:2078–92. doi:10.1056/NEJMoa1801005.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.